KORU Medical shares surge 14.55% after-hours after raising revenue guidance and reporting strong Q3 earnings, maintaining Buy rating.

KORU Medical (NASDAQ: KRMD) surged 14.55% in after-hours trading following the reiteration of a "Buy" rating by Canaccord Genuity with a $5.00 price target, alongside raised revenue guidance to 20-22% growth and Q3 earnings that exceeded expectations. The company reported $10 million in revenue for the second consecutive quarter, driven by 27% year-over-year growth and strong international performance. Analysts highlighted expansion in subcutaneous immunoglobulin markets, non-recurring engineering revenue, and global tender opportunities as key catalysts. The stock’s sharp rise aligns with these bullish factors, which underscore improved investor confidence in KORU’s growth trajectory and product pipeline advancements.